Breaking News

Aduro, Janssen Ink Immunotherapies License Agreement

May 29, 2014

Janssen to take on prostate cancer candidates

Aduro BioTech, Inc. has entered an agreement granting Janssen Biotech an exclusive, worldwide license to certain product candidates for the treatment of prostate cancer based on its LADD immunotherapy platform.
Aduro is eligible to receive as much as $365 million in upfront license fees and milestone payments based on development, regulatory and commercialization milestones, should multiple programs advance to commercialization, as well as royalties on sales.
Janssen will be responsible for all research, development, manufacturing, regulatory and commercialization for the licensed products. Under a separate agreement, Aduro has granted Janssen exclusive rights to its GVAX technology for prostate cancer.
“We are pleased to provide Janssen with novel immunotherapies engineered specifically for this indication,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We believe this is an important validation of our platform strategy and we are excited to have the Janssen development team taking the lead in advancing the prostate cancer program. Separately, we look forward to continued progress with our LADD platform in a broad array of other oncology indications, including pancreatic cancer, mesothelioma, non-small cell lung cancer and glioblastoma among others.”

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent